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1. Introduction
Matrix metalloproteinases (MMPs) represent a family of
dependent metal ion endopeptidases, which are capable of
degrading all extracellular matrix (ECM) components.1 MMPs
are classified by substrate specificity into collagenases,
gelatinases, stromelysins, and membrane-bound types.2
MMP expression is regulated by cytokines. Whereas T-helper
type 1 (Th1) and the inflammatory mediators interleukin (IL)-
1b, tumour necrosis factor (TNF)-a, and interferon (IFN)-g have
been described as positive regulators of MMP expression, the
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 9 5 4 – 9 6 3
a r t i c l e i n f o
Article history:
Accepted 28 January 2012
Keywords:
Chronic periodontitis
End-stage renal disease
MMP-1
Genetic polymorphisms
Transcript levels
a b s t r a c t
Chronic periodontitis (CP) and end-stage renal disease (ESRD) are complex inflammatory
conditions. Higher levels of MMP-1 were found in fluids and gingival tissues from CP patients
and in the blood and tissues from ESRD patients. MMP1-1607 (1G/2G) is a functional
polymorphism, as it alters MMP-1 expression.
Objective: The aim of this study was to investigate the association of the MMP1-1607 (1G/2G)
polymorphism with CP and ESRD and evaluate differences in transcript levels between the
groups.
Design: A total of 254 individuals were divided into four groups: Group 1, without CP and
without chronic kidney disease (CKD) (n = 67); Group 2, with CP and without CKD (n = 60);
Group 3, without CP and with CKD stage 5 (ESRD) (n = 52), and Group 4, with CP and with ESRD
(n = 75). The MMP1-1607 polymorphism was analysed by PCR-RFLP. MMP1 gene transcripts
from gingival tissues were analysed by real-time PCR.
Results: No association was found between the MMP1-1607 polymorphism and CP or ESRD.
Increased levels of MMP1 transcripts were observed in CP patients with or without ESRD. No
differences were observed in the transcript levels according to the genotypes.
Conclusion: It was concluded that the MMP1-1607 polymorphism was not associated with
either CP or ESRD. However, higher levels of MMP1 gene transcripts were found at gingival
sites of CP in patients both with and without ESRD.
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reverse effect is exerted by the Th2-type cytokines, such as IL-
4, IL-10 and IL-13.3 The activation of MMPs is regulated by a
group of endogenous proteins called tissue inhibitors of
metalloproteinases (TIMPs) that are each able to inhibit nearly
every member of the MMP family in a non-specific manner.4
MMPs play an important role in physiological events during
embryonic development, morphogenesis, angiogenesis, and
tissue repair5 and are overexpressed in several diseases, such
as ovarian cancer,6 atherosclerosis,7 and osteoarthritis.8 By
their ability to degrade ECM, MMPs are at the crossroads of
several disease progression and regression pathways.
Chronic periodontitis (CP) is a multifactorial disease in
which the susceptibility, progression and outcome are
dependent on multiple environmental and genetic factors.9
CP is a highly prevalent infectious illness of the oral cavity that
may affect at least 50% of adults, initiated by gram-negative
bacteria and characterised by inflammatory cell accumulation
in the periodontal tissues.10 It has been suggested that, in
periodontal lesions, the balance between the expression of
Th1- and Th2-type cytokines in a mixed inflammatory
immune response is a relevant factor to the outcome of
disease.11 The inflammatory reaction is thought to trigger
periodontal tissue destruction as a consequence of an
imbalance in the expression of MMPs versus (vs.) TIMPs,
which act to regulate extracellular matrix turnover of
periodontal tissues, including alveolar bone.12 The transcrip-
tional levels and activity of MMPs are significantly higher in
gingival tissues of individuals with CP than in healthy
patients13 and, as a consequence, destructive periodontal
disease occurs in CP individuals.10
An emerging body of evidence suggests that oral inflam-
matory diseases, and particularly periodontal infections, may
not be limited to the immediate oral environment but can have
systemic effects.14 Periodontitis has been considered as a
complicator for several systemic diseases, such as chronic
kidney disease (CKD),15 and its prevalence and severity are
thought to be increased within this disease population.16
Destructive CP may be a significant source of inflammation in
compromised patients when periodontal evaluations are not
performed as part of a medical assessment.17
Chronic kidney disease is a progressive disorder associated
with a number of systemic complications that is characterised
by the destruction of the kidneys’ functional units (nephrons)
resulting from a profound hydroelectrolytic, metabolic and
immunological imbalance.18 CKD can result from a wide
spectrum of diseases, such as diabetes, hypertension,
glomerulonephritis, and autoimmune disorders.19 Kidney
disease is divided into five stages of increasing severity.20
Independently of its aetiology, CKD can progress to an
advanced stage, or renal disease stage 5, and designated as
end-stage renal disease (ESRD) in which the signs and
symptoms of uraemia (uraemic syndrome) predominate.
Remodelling of the ECM is a key event in the progression
and reversal of kidney disease. CKD results from a process in
which there is disequilibrium between the increased synthesis
of ECM components and decreased ECM degradation, primar-
ily by MMPs that are under the control of TIMPs. In the kidney,
MMPs are assumed to be important players because they
cleave basement membrane (BM) components, primarily type-
IV collagen.21 In fact, BM damage is a major event in crescentic
glomerulonephritis. Conversely, the excessive matrix accu-
mulation observed in the fibrotic kidney results from a
combination of overproduction and defective degradation of
matrix components.21 However, considering the multiplicity
of their targets and the complexity of their regulation, MMP-
mediated effects may be different and even opposite during
the different phases of the evolution of nephropathies. As
described for CP, altered cytokine production may result in the
disturbance of MMP/TIMP balance.22 In fact, excessive or
inappropriate expression of MMPs has been associated with
CKD complications, such as progressive renal injury, glomer-
ular sclerosis,23 interstitial kidney fibrosis,24 and cardiovascu-
lar diseases.25
MMP-1 is a collagenase produced by fibroblasts, keratino-
cytes, endothelial cells, macrophages, osteoblasts and chon-
drocytes.26 This enzyme is secreted as an inactive pro-enzyme
(zymogen), and its activation occurs in the tissue by cleavage
of the N-terminal pro-peptide domain by other proteinases.27
MMP-1 is the major proteolytic enzyme that can cleave native
interstitial collagen type I and III, which are the most abundant
protein components of the ECM. Therefore, variance in MMP-1
transcription levels may be relevant to the progression of both
CP and CKD. The MMP1 gene is located in 11q2228 and includes
several functional polymorphisms located in the promoter
region.29 An insertion/deletion of a guanine at position -1607
of the human MMP1 gene creates two different alleles: one
with a single guanine (1G) and another with two guanines
(2G).30 It has been shown that the 1G/2G polymorphism is
functional because the allele 2G significantly increases the
transcriptional activity of MMP-1.30 The presence of the allele
2G was observed to be associated with ovarian cancer,31 renal
carcinoma,32 and CP.33
Although there are a few studies of ESRD and CP that
investigate their association with the MMP1-1607 gene
polymorphism, there is no study investigating the association
of the MMP1-1607 gene polymorphism with CP in ESRD
patients. Thus, the aim of the present work was to analyse
the association between the MMP1-1607 polymorphism and
MMP1 transcript levels with CP and ESRD.
2. Materials and methods
2.1. Study population
A sample of 254 unrelated patients of both genders with a
mean age of 44.6 years (range 20–77) was selected from the
Dental Clinics of Pontifical Catholic University of Parana´
(PUCPR) and from the Dental Clinics of the Pro-Renal
Foundation over a period of two years between 2007 and
2009. All patients were from the southern region of Brazil. The
baseline clinical parameters for the entire population are
listed in Table 1. Although the study sample was primarily
composed of Caucasians, the Brazilian white population is
heterogeneous. A recent article suggested not to group
Brazilians into ethnic groups based on colour, race and
geographical origin because Brazilian individuals classified
as white or black have significantly overlapping genotypes,
probably due to miscegenation.34 According to the Brazilian
Government Census (2005), in southern Brazil, the racial
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composition is 77.8% white, 2.2% black, 18.9% mixed-race, and
1.1% Japanese. Amongst the white population, there is a
predominance of Italian, Spanish, and Portuguese heritage. All
subjects completed personal, medical and dental history
questionnaires that were within a protocol approved by an
Institutional Review Board, and all participants signed consent
forms after being advised of the nature of the study (approved
by the Ethical Committee in Research at PUCPR, protocol 264/
10184).
The sample was divided into 4 groups:
Group 1: 67 individuals without CKD (glomerular filtration
rate >90 mL/min estimated according to the Modification
of Diet in Renal Disease formula)35 and without CP;
Group 2: 60 patients without CKD and with CP [clinical
attachment loss (CAL)  5 mm, in at least 3 teeth, in at least
2 quadrants];
Group 3: 52 patients with CKD stage 5 (ESRD), in haemo-
dialysis, and without CP; and
Group 4: 75 patients with CKD stage 5 (ESRD), in haemo-
dialysis, and with CP.
All CKD patients underwent dialysis sessions with poly-
sulfone low-flux membranes, and the dialysate calcium
concentrate was 3.5 mg/L during the study. The dialysis time
(3.5–5 h) and dose was delivered to achieve a Kt/V above 1.2.
Haemoglobin levels were monitored to achieve the K/DOQI
recommended parameters, and all patients were placed on
epoetin alpha therapy. The target for ferritin was between 200
and 800 ng/mL, and intravenous iron saccharose was used
when needed. Calcitriol and phosphorus binders were
prescribed as needed to achieve the mineral metabolism
targets recommended by the K/DOQI guidelines.
Patients were not included if they presented chronic use of
anti-inflammatory drugs, AIDS, immunosuppressive chemo-
therapy, systemic active infection, current pregnancy or
lactation, use of orthodontic appliances, or presence of
necrotising ulcerative gingivitis or periodontitis. Smokers
were included, but only 37/254 (14.5%) claimed smoking
habits, and no statistically significant difference was observed
between the groups with and without CP in patients with and
without ESRD.
2.2. Clinical parameters for CP
Diagnosis of CP was made based on clinical parameters, such
as probing pocket depth (PPD) and assessment of CAL.
Measurements of PPD and CAL were recorded at 4 points
around each tooth. Subjects with CAL > 5 mm, in at least 3
teeth and at least 2 quadrants, were considered affected.36 The
following parameters were recorded: gingival index (GI),37
plaque index (PI),38 calculus index (CI),39 and mobility (absent
or present). The periodontal status of all subjects is shown in
Table 2.
2.3. Biochemical parameters of ESRD patients
The following blood cells and serum markers were measured
according to the routine of the Dialysis Clinics for ESRD patients:
C-reactive protein, creatinine, protein catabolic rate, cal-
cium  phosphorus, Kt/V (a marker of dialysis adequacy),
percentage of reduction urea, urea, potassium, haematocrit,
alanine aminotransferase (ALT), albumin, iron, glucose, calci-
um, phosphorus, ferritin, transferrin, iron saturation index,
haemoglobin, alkaline phosphatase, leukocytes, and alumini-
um. The general clinical aspects of ESRD patients either without
(group 3) or with (group 4) CP can be found in Table 3.
2.4. Analysis of MMP1-1607 (1G/2G) polymorphism by
polymerase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP)
Cells were obtained through a mouthwash with 3% glucose
solution and scraping of the oral mucosa with a sterile
spatula.40 DNA was extracted from epithelial buccal cells with
8 M ammonium acetate and 1 mM EDTA.41
Table 1 – Baseline characteristics of the study population.
Group 1*
(n = 67)
Group 2y
(n = 60)
Group 3z
(n = 52)
Group 4§
(n = 75)
p value
Ethnic Group, n (%)
Caucasoid 53 (79.1) 46 (76.7) 38 (73.1) 52 (69.3) 0.646
Mulatto 10 (14.9) 13 (21.7) 12 (23.1) 18 (24.0)
Afro-American 4 (6.0) 1 (1.7) 2 (3.8) 5 (6.7)
Age (years)
(range)jj
38.4  9.5
(20–70)
41  9.3
(20–61)
45.3  2.5
(23–74)
53.8  12.1
(26–77)
<0.001#
Gender, n (%)
Female 49 (73.1) 40 (66.7) 18 (34.6) 26 (34.7) <0.001
Male 18 (26.9) 20 (33.3) 34 (65.4) 49 (65.3)
Smoking, n (%)£ 5 (7.5) 3 (5.1) 10 (20.4) 19 (26.0) 0.001
Diabetes, n (%)£ 1 (1.5) 1 (1.7) 7 (14.3) 19 (26.0) <0.001
* Healthy patients (no renal or periodontal disease).
y With CP and without CKD.
z Without CP and with ESRD.
§ With CP and with ESRD.
 Chi-squared.
jj Mean  standard deviation.
# ANOVA.
£ Group 3 (n = 49) and group 4 (n = 73).
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 9 5 4 – 9 6 3956
The following primer pair was used for PCR amplification
of genomic DNA samples for the MMP1-1607 (rs1799750) gene
polymorphism: (F: 50-TCG TGA GAA TGT CTT CCC ATT-30 and
R: 50-TCT TGG ATT GAT TTG AGA TAA GTG AAA TC-30).
Reaction conditions and cycling parameters were as follows:
1 mL of the genomic DNA was used for PCR amplification in a
reaction mixture containing 12.5 mL of PCR Supermix (Go Taq
Green Master Mix, Promega, Madison, WI, USA) and 1 mL of
each 25 mM primer. The reactions were performed in a
thermal cycler (Techne T-512, Barloworld Scientific US Ltd.,
Burlington, NJ, USA) and consisted of an initial denaturation
step of 95 8C for 5 min, followed by 35 cycles of 95 8C for 1 min,
55 8C for 1 min, 72 8C for 1 min, and a final extension of 72 8C
for 7 min.
A 10-mL aliquot of PCR products was mixed with a
solution (New England Biolabs, Inc., Beverly, MA, USA)
containing 2 mL 10 NE Buffer (50 mM NaCl, 10 mM Tris–HCl,
10 mM MgCl2, 1 mM dithiothreitol, pH 7.9), 0.02 mL bovine
serum albumin (BSA, 10 mg/mL), 0.3 mL XmnI (20 units/mL)
and 8 mL sterile deionised H2O. The solution was incubated
at 37 8C overnight. Two mismatches were introduced in the
reverse primer that annealed in the proximity of the
polymorphism,42 which created a recognition sequence
(50-GAANNNNTTC-30) for the restriction endonuclease XmnI
(Invitrogen, San Diego, CA, USA) when the DNA template
contains 1G (but not 2G) at the polymorphism site. Thus,
XmnI digests the 1G allele, creating two fragments of 89 bp
and 29 bp.
The full amount of the digest was electrophoresed on a 10%
vertical non-denaturing polyacrylamide gel at 30 mA. The gel
was silver stained with the DNA Silver Staining Kit (Amersham
Pharmacia Biotech AB, Uppsala, Sweden).
2.5. Analysis of MMP1 gene transcripts by real-time PCR
The pattern of mRNA expression for the MMP1 gene was
investigated by real-time PCR and associated with geno-
types in the entire population and within each group. From
each group, 15 patients (n = 60) were randomly scheduled for
biopsies of gingiva (comprising crevicular and junctional
epithelium and connective tissue). The gingival sites from
each biopsy represented extreme phenotypes (groups 1 and
3: healthy sites, with no signs of inflammation and
attachment loss; groups 2 and 4, presenting bleeding and
suppuration, and clinical attachment loss of at least 5 mm).
TRIzol (Invitrogen, San Diego, CA, USA) extraction of total
RNA from periodontal tissues samples and cDNA synthesis
were accomplished as previously described.43
Real-time PCR quantitative mRNA analyses were per-
formed in a MiniOpticon system (BioRad, Hercules, CA, USA)
using the SYBR-green fluorescence quantification system
(Applied Biosystems, Foster City, CA, USA) for quantitation
of amplicons as previously described.43 The standard PCR
conditions were 95 8C (10 min), followed by 40 cycles of 94 8C
(1 min), 56 8C (1 min) and 72 8C (2 min), and a standard
denaturation curve. Real-time PCR conditions for each
target were optimised with respect to the primer concen-
tration, the absence of primer-dimer formation, and the
efficiency of amplification of the target genes and the
housekeeping control gene. The SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA), 400 nM
of specific primers [MMP1 sense TGGACCTGGAG-
GAAATCTTGC, anti-sense AGAGTCCAAGAGAATGGCCGA;
b-actin: sense ATGTTTGAGACCTTCAACA, anti-sense
CACGTCAGACTTCATGATGG] and 2.5 ng of cDNA were used
in each reaction, as previously described.44 For mRNA
analysis, the relative level of gene expression was calculated
in reference to b-actin using the cycle threshold (Ct)
method. The threshold for positivity of real-time PCRs
was determined based on the negative controls (reactions
performed without RNA and without reverse transcriptase).
The mean Ct values from duplicate measurements were
used to calculate the expression of the target gene,
normalised to an internal control (b-actin), using the 2(DDCt)
DCt) formula.
2.6. Statistical analysis
The significance of the differences in the observed frequen-
cies of polymorphism between the groups was assessed by
standard chi-squared (x2) tests. Comparisons between the
two groups for nominal variables in 2  2 tables were
Table 2 – Periodontal status of the study population.
Periodontal indices Group 1*
(n = 67)
Group 2y
(n = 60)
Group 3z
(n = 52)
Group 4§
(n = 75)
p value
Gingival Index 0.2  0.4 1.6  1.0 0.4  0.6 0.8  0.9 <0.001**
Plaque Index 0.3  0.4 1.3  1.0 0.6  0.9 1.1  1.0 <0.001**
Calculus Index 0.2  0.2 0.9  0.9 0.4  0.8 0.8  0.9 <0.001**
PPDjj (mm) 1.5  0.1 2.0  0.5 1.3  0.6 1.7  0.7 <0.001**
CAL# (mm) 1.5  0.1 2.3  0.9 1.3  0.6 2.4  1.4 <0.001**
Mobility (absence/presence) 65/2 35/24 37/12 37/34 <0.001yy
* Healthy patients (no renal or periodontal disease).
y With CP and without CKD.
z Without CP and with ESRD.
§ With CP and with ESRD.
 Mean  standard deviation.
jj Probing pocket depth.
# Clinical attachment loss.
** ANOVA.
yy Chi-squared.
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performed using Fisher’s exact test. Statistical analysis was
performed using statistical software (BioEstat 2.0 for
Windows and Statistical Package for the Social Sciences
10.0 for Windows, Inc., Chicago, IL, USA). For continuous
variables, Student’s t tests were used to compare the means
of two groups. For non-parametric variables, the Mann–
Whitney U test was used to assess differences between the
groups. Continuous variables were expressed as the mean
and standard deviation, and comparisons were performed
using one-way analysis of variance (ANOVA), followed by
Tukey’s test. The normal condition of the variables in each
group was evaluated using the Shapiro–Wilks test. All
statistical tests for gene transcripts were performed on
graphic software (GraphPad InStat 3.05 and GraphPad Prism
3.0 software, GraphPad Software, Inc.). For all the tests,
values of p < 0.05 were considered statistically significant.
3. Results
3.1. Genotyping analysis
The genotype distribution for the MMP1-1607 polymorphism
was consistent with the assumptions of Hardy–Weinberg
equilibrium. There was no statistically significant difference in
the MMP1 polymorphism genotype distribution ( p = 0.348)
between the groups or in the allele frequency ( p = 0.397) for the
polymorphism studied. Genotypic frequencies and allelic
distribution are shown in Table 4. When group 1 (control)
vs. group 2 (patients with CP) was examined, no significant
difference was noted for both the genotypic ( p = 0.335) and
allelic ( p = 0.956) distributions. The same was true for the
group 1 (control) vs. group 3 (patients with ESRD) genotypic
( p = 0.145) and allelic ( p = 0.212) frequencies as well as for the
Table 3 – General clinical aspects of ESRD patients.
Group 3b
Without CPa
(n = 52)
Group 4b
With CPa
(n = 75)
p value
Duration of HDc treatment (months)y 43.2  41.2 45.4  42.3 0.783
General medical condition, n (%)
Diabetes 7 (14.3) 19 (26.0) 0.176
Hepatitis 9 (18.3) 20 (27.4) 0.285
CVDd 10 (20.4) 18 (24.6) 0.664
Hypertension 31 (63.3) 61 (83.5) 0.017*
Current medication, n (%)
Antihypertensives 35 (71.4) 55 (75.3) 0.678
Diuretics 11 (22.4) 30 (41.1) 0.050
Calcium carbonate 34 (69.4) 52 (71.2) 0.842
Vitamin D (calcitriol) 9 (18.3) 12 (16.4) 0.810
Antiplatelet agents 2 (4.1) 9 (12.3) 0.196
Others 40 (81.6) 59 (80.8) 1
Habits, n (%)
Smoking 10 (20.4%) 19 (26.0) 0.522
Laboratory measurementsy
CRPe (mg/L) 7.7  10.4 12.7  17.9 0.030**
Serum creatinine (mg/L) 10.1  2.7 9.8  2.8 0.572
Normal protein catabolic rate 0.9  0.2 0.9  0.2 0.804
Kt/Vf 1.3  0.2 1.2  0.2 0.153
Serum calcium (mg/dL) 8.9  0.7 9.1  0.7 0.229
Serum phosphorus (mg/dL) 5.3  1.1 6.3  1.2 0.000#
Serum calcium–phosphorus product (mg/dL) 50  12.7 51.5  12.8 0.509
Serum potassium (mg/dL) 5.2  0.5 5.3  0.6 0.579
PTHig 493.8  593.1 468.7  557.6 0.739
Serum alkaline phosphatase 131.7  128.6 124.3  107.1 0.793
Serum albumin (mg/dL) 3.7  0.3 3.6  0.3 0.260
Ferritin 700.7  291.0 710.1  299.1 0.865
Leucocytes 6756.9  1402.7 7108.1  2336.0 0.308
Haemoglobin 11.5  1.4 11.3  1.5 0.637
Haematocrit (%) 34.7  4.3 34.1  4.6 0.503
Note: Missing data were not included.
a Chronic periodontitis.
b Chronic kidney disease.
c Haemodialysis.
d Cardiovascular disease.
e C-reactive protein.
f Marker of dialysis adequacy.
g Serum intact parathormone.
y Mean  standard deviation.
* Fisher’s test.
** Mann–Whitney U test.
# Student’s t test.
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group 1 (control) vs. group 4 (patients with ESRD and CP)
genotype ( p = 0.582) and allele ( p = 0.359) distributions.
3.2. Genotyping and CP clinical parameters
With respect to the clinical periodontal status, the MMP1-
1607*1G allele was associated with a higher mean PI in
individuals without CKD (groups 1 and 2) ( p = 0.045). In
addition, an association between the 1G allele with PPD
( p = 0.053) and CAL ( p = 0.042) in ESRD patients (groups 3 and 4)
was observed.
3.3. Genotyping and ESRD clinical parameters
In ESRD patients (groups 3 and 4), higher levels of two serum
markers were associated with the MMP1*2G allele: ALT
( p = 0.026) and calcium ( p = 0.014). The MMP1*1G allele was
associated with higher levels of ferritin ( p = 0.030).
With respect to clinical aspects of ESRD, an association
( p = 0.003) between the MMP1*2G allele and hepatitis was
observed.
3.4. Analysis of MMP1 gene transcripts
There was an augmentation in the expression of the MMP1
gene in groups with CP (groups 2 and 4). Although the levels
of expression were higher in group 4 compared with group
2, a statistically significant difference was not observed
(Fig. 1).
No statistically significant difference was observed in
relation to the MMP1-1607 genotype distribution in the entire
sample. In group 4, there was an increase in MMP1 transcripts
in the presence of the 2G allele, but no statistically significant
difference was observed (Fig. 2).
4. Discussion
Matrix metalloproteinases play an important role in both the
degradation and remodelling of ECM proteins during different
physiological and pathological processes.45 At physiological
conditions, TIMPs are in balance with the MMPs, and the ECM
is remodelled in a highly regulated fashion. However, in many
cases, the levels of MMPs are elevated without a concomitant
increase in TIMPs, resulting in tissue destruction, as observed
in some inflammatory diseases, such as CP44 and CKD.46
In the present study, no significant difference was observed
in the genotype distribution or in the allele frequency for the
MMP1-1607 polymorphism between the groups. One limita-
tion of this study was the small number of individuals in each
group; genetic studies are more powerful as the sample size
increases. Small samples could be a major cause of ‘‘negative
results’’ in the experimental analysis, and if the N is not high
enough to support definitive statements, the findings must be
replicated in other populations. Another limitation might be
the diagnosis of chronic periodontitis based only on clinical
parameters, as radiographs were not used to define pheno-
types in this study, and different manual probe pressures
between examiners may affect the accuracy and reproducibil-
ity of diagnoses.
MMP1-1607 is a functional polymorphism, and there are a
small number of studies investigating its association with
CP.33 The MMP1-1607 polymorphism was investigated for CP in
Asiatic populations. No association of the polymorphism with
CP in Japanese patients was reported, although the 2G/2G
Table 4 – Allelic and genotypic distribution of MMP1-1607 (1G/2G) gene polymorphism.
Group 1* Group 2y Group 3z Group 4§ Chi-squared
p value
Genotype n = 67 (%) n = 60 (%) n = 52 (%) n = 75 (%)
1G/1G 18 (26.9) 11 (18.3) 7 (13.5) 13 (17.3) x2 = 6.71
p = 0.3481G/2G 26 (38.8) 32 (53.3) 26 (50.0) 31 (41.3)
2G/2G 23 (34.3) 17 (28.3) 19 (36.5) 31 (41.3)
Allele n = 134 (%) n = 120 (%) n = 104 (%) n = 150 (%)
1G 62 (46.3) 54 (45) 40 (38.5) 57 (38) x2 = 2.96
p = 0.3972G 72 (53.7) 66 (55) 64 (61.5) 93 (62)
* Healthy patients (no renal or periodontal disease).
y With CP and without CKD.
z Without CP and with ESRD.
§ With CP and with ESRD.
Fig. 1 – Quantitative expression of the MMP1 gene in
gingival tissues of patients from the four groups. Total
RNA was extracted, and the levels of MMP1 were
measured quantitatively by the real-time PCR SYBR-Green
System. The results are presented as the fold increase of
expression of the mRNA, normalised to b-actin, and
compared with the target-internal control using the cycle
threshold (Ct) method.
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 9 5 4 – 9 6 3 959
genotype, 2G allele frequency and 2G carriage rate were
increased in cases of severe CP.47 Moreover, the frequency of
the 2G allele and the 2G/2G genotype was higher in subjects
with severe periodontitis in a Chinese population.48 There has
been some discrepancies in the results of different analyses of
this polymorphism in Brazilian populations. Astolfi et al.49
observed no association of genotypes and alleles of the MMP1-
1607 polymorphism with CP groups. However, a different
study reported an association of the MMP1*2G allele with
severe CP.33 More recently, two studies in Turkish populations
showed different results. Pirhan et al.50 reported an associa-
tion of the MMP1*2G allele with severe periodontitis, and no
association was found of this allele with periodontitis in the
study by Ustun et al.51 These discrepancies may reflect the
involvement of variable combinations of risk alleles in
different populations, confounding factors such as genetic
admixture, regional differences in gene frequencies, gene–
environment interactions, and a poor sample selection of
extreme phenotypes.52 In fact, we observed that most studies
considering extreme phenotypes (especially severe diseases)
were able to detect an association between the MMP1-1607
gene polymorphism and CP.33,48,50 Thus, these data may
indicate that the MMP1-1607 gene polymorphism is associated
with CP severity rather than susceptibility.
No difference was observed in the frequency of genotypes
and alleles between ESRD and control patients. It was
observed in Japanese subjects that the MMP1-1607*1G allele
was significantly associated with CKD53 and with CKD in
individuals with a low serum concentration of HDL-choles-
terol.54
Interestingly, with regard to periodontal indices, we found
that the MMP1*1G was associated with PI in groups without
CKD. Based on the presence of both periodontal bacteria and
interleukins (e.g., IL-1, IL-6), which regulate MMP-1 expres-
sion, an association of the MMP1*2G allele with higher means
of PI might be expected; however, dental biofilm represents a
more favourable environment for the initiation rather than
the progression of CP.55 Disease progression and severity may
be further dependent on the immune-inflammatory host
response to microbial challenge.11 MMP1*1G was also associ-
ated with higher means of PPD and CAL in ESRD patients,
although the expected association was with the 2G allele. In
an inflamed systemic environment, such as in ESRD patients,
it is possible that some complex gene expression regulation
may occur.
An association between the MMP1*2G allele and higher
levels of both ALT and hepatitis was found. The transami-
nases, such as ALT, are considered to be ‘‘classical’’ serum
markers of liver necro-inflammatory injury.56 It is recom-
mended that patients on haemodialysis therapy, who
constitute a risk group for hepatitis C virus (HCV) infection,
submit to regular screening for HCV infection using ALT
values.57 HCV infection is frequently asymptomatic in these
patients and should be suspected in all patients presenting
elevated ALT.58 The prevalence of HCV is significantly higher
in haemodialysis and kidney transplant patients than in the
general population.59 Chronic HCV infection remains an
important cause of liver disease in patients with ESRD, and
renal failure has a significant impact on morbidity and
mortality throughout the natural history of chronic HCV.60
The MMP1*1G allele was also associated with higher levels of
ferritin. Serum ferritin is a clinically important index of body
iron stores, but its functional role remains largely obscure.61
When ferritin is also considered as an acute-phase reactant,62
inflammatory factors may interfere with the synthesis and
clearance of ferritin, thereby increasing serum ferritin levels
in a manner unrelated to the iron status.63 Higher levels of
serum calcium were associated with the MMP1*2G allele.
Current clinical guidelines recommend that serum levels of
calcium and phosphorus should be maintained within the
target range to avoid the development of vascular calcifica-
tion.64 The kidney plays a leading role in maintaining calcium
and phosphorus homeostasis in collaboration with other
organs, such as the parathyroid gland, intestines, and bones.
Along with the progression of CKD, various abnormalities of
mineral and bone metabolism may exist.65 Traditionally,
such disorders have been considered with regard to the bone
lesion itself, but it has become increasingly evident that
mineral and bone disorders have a critical role in the
pathogenesis of extraskeletal calcification, including in the
vasculature, which results in cardiovascular complications
and mortality.66 In addition, it was recently reported that the
Fig. 2 – Quantitative expression of the MMP1 gene in gingival tissues of patients from the four groups according to genotype:
1G/1G, 1G/2G, 2G/2G. Total RNA was extracted, and the levels of MMP1 were measured quantitatively using the real-time
PCR SYBR-Green System. The results are presented as the fold increase of expression of the mRNA, normalised to b-actin,
and compared with the target-internal control using the cycle threshold (Ct) method.
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2G allele is associated with mortality in haemodialysis
patients.67
MMP1 gene transcripts were analysed in patients present-
ing CP and ESRD and in control patients. The levels of MMP1
transcripts were higher in the group with CP and ESRD (group
4) compared with the group with only CP (group 2), but no
significant difference was observed. Excessive or inappropri-
ate expression of MMPs has been associated with progressive
renal injury, glomerular sclerosis23 and interstitial kidney
fibrosis.24 Preston et al.68 indicated that there are measurable
differences in the expression of MMPs within the dialysis
patient population. Because dialysis can be associated with
local and systemic inflammation, increased levels of certain
MMPs in haemodialysis groups may be a reflection of gene
stimulation induced by inflammatory cytokines. Moreover, in
the group with both diseases, there was a progressive
increase of MMP1 transcripts in the presence of the 2G allele.
It was previously reported that an additional guanine (G)
creates an Ets (a family of transcription factors)-binding site,
promoting significantly increased transcription in normal
fibroblasts, thereby providing a mechanism for more aggres-
sive matrix degradation.30 Perhaps in the presence of a
systemic disease, the association of the 2G allele with the
augmentation of gene expression in CP is more evident.
Furthermore, the presence of a high variation in MMP1
expression between individuals with the same genotype in
groups with CP was noted. This could be due to the additional
influence of specific periodontopathogens and cytokine
stimulation.
Chronic infections, such as CP, appear to be significant
causes of persistent systemic inflammation in patients with
ESRD69 and, in turn, systemic conditions, such as ESRD, may
impact CP outcome.70 Moreover, MMPs are overexpressed in
inflammatory conditions, such as CP and ESRD, increasing the
destruction of ECM components. Thus, investigating poly-
morphisms that interfere with the regulation of MMP
expression may contribute to an understanding of common
genetic mechanisms.
In summary, no evidence for the association of MMP1-1607
(1G/2G) with susceptibility to CP or ESRD was observed.
However, other polymorphisms in MMP genes may have an
impact on the response to CP and ESRD inflammatory insult.
An augmentation of the levels of MMP1 gene transcripts in
periodontally affected tissues of patients with and without
CKD was observed.
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